Anzeige
Mehr »
Login
Samstag, 27.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
BRANDNEUE Gold-Entdeckung: OMEGA stößt auf HOCHGRAD-Gold! 18,98 m @ 6,22 g/t Gold! TA-Preis "STARKER-KAUF"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2F2 | ISIN: US33749P4081 | Ticker-Symbol: 366
NASDAQ
26.07.24
21:59 Uhr
0,820 US-Dollar
-0,140
-14,58 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENTERO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ENTERO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ENTERO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrEntero Therapeutics files secondary offering of 3.5M shares1
DiEntero Therapeutics, Inc. - 8-K, Current Report1
11.07.Entero Therapeutics, Inc. - 8-K, Current Report3
09.07.Entero Therapeutics, Inc.: Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium5
27.06.Entero Therapeutics, Inc.: Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease4
24.06.Entero Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
20.06.Entero Therapeutics, Inc. - 8-K, Current Report3
05.06.Entero Therapeutics, Inc. - 8-K, Current Report3
22.05.Entero Therapeutics, Inc.: Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention4
21.05.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.05.20242.027The following instruments on Boerse Frankfurt do have their last trading day on 21.05.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.05.2024.ISIN NameCA00379L1067 ABRASILV....
► Artikel lesen
20.05.Entero Therapeutics, Inc.: Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference3
17.05.First Wave BioPharma comes ashore with new name as it prepares for phase 3 trial5
16.05.First Wave BioPharma Rebrands to Entero Therapeutics3
16.05.First Wave BioPharma changes name to Entero Therapeutics3
16.05.First Wave BioPharma, Inc. Changes Name to Entero Therapeutics, Inc.228Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset - latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is "ENTO" effective May 17, 2024...
► Artikel lesen
14.05.First Wave BioPharma, Inc. - 10-Q, Quarterly Report2
13.05.First Wave BioPharma, Inc. - 8-K, Current Report1
10.05.First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market3
24.04.First Wave BioPharma, Inc.: First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients2
17.04.First Wave BioPharma, Inc.: First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase3
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1